Association between body mass index and efficacy of neoadjuvant targeted therapy in HER2-positive breast cancer in a Chinese multicenter cohort
Chengye Hong, Peidong Yang, Debo Chen, Weibin Lian · 2025
Read Association between body mass index and efficacy of neoadjuvant targeted therapy in HER2-positive breast cancer in a Chinese multicenter cohort by Chengye Hong, Peidong Yang, Debo Chen, Weibin Lian (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12657506.txt.
Description
A peer-reviewed research article from Europe PMC (2025). Overweight/Obesity, characterized by body mass index (BMI) ≥ 25 kg/m2, is recognized as a significant prognostic factor in HER2-positive breast cancer, yet its precise influence on neoadjuvant targeted therapy response remains incompletely understood. To address this critical knowledge gap, we conducted a multicentre retrospective cohort study investigating the impact of BMI on pathological complete response (pCR) among HER2-positive breast cancer patients undergoing neoadjuvant targeted therapy. The study comprised 826 Chinese patients from January 2013 to June 2024.
Catalog record
| CREATOR | Chengye Hong, Peidong Yang, Debo Chen, Weibin Lian |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |